Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study


ABSTRACT

BACKGROUND AND PURPOSE: Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area.

MATERIALS AND METHODS: We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020.

RESULTS: Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36–62 years; range, 17–95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%.

CONCLUSIONS: Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.

ABBREVIATIONS: COVID-19 = coronavirus disease 2019; CVST = cerebral venous sinus thrombosis; CVT = cerebral venous thrombosis; SARS-CoV-2 = Severe Acute Respiratory Syndrome coronavirus 2
COVID-19.\textsuperscript{10} It remains unknown whether infection with the SARS-CoV-2 virus can also lead to cerebral venous thrombosis (CVT).

**MATERIALS AND METHODS**

We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020, in 6 academic, tertiary care facilities that are also designated as comprehensive stroke centers in the New York City metropolitan area. The number of hospital beds ranged from 500 to 1100. The patients were identified by conducting a retrospective review of prospectively maintained stroke data bases in each of these collaborating centers. The goal of our study was to characterize the frequency and demographic and clinical characteristics of hospitalized patients with SARS-CoV-2 who developed CVT. This study was approved by the individual enrolling hospitals’ institutional review board centers.

**Clinical Management**

Clinical management of CVT conformed to the American Heart Association/American Stroke Association and Society of Neurointerventional Surgery guidelines.\textsuperscript{11,12} The diagnostic criteria and classification of COVID-19 severity was defined by the American Thoracic Society criteria.\textsuperscript{13}

**Data Collection**

Comprehensive data on each patient were collected, including demographics, medical history, baseline clinical status, imaging results and treatment, and complications during hospitalization. Clinical data for COVID-19 diagnosis and management were retrieved from the medical records as well, which included demographic features, medical history, clinical symptoms, laboratory findings, lung CT findings on admission, treatment regimens, and clinical outcomes. Prior prothrombotic risk was defined as any history of a clinically significant thromboembolic event.

**Clinical and Radiologic Variables**

The diagnosis of the CVT was established by admission CT or MR venography. All included patients also underwent a noncontrast CT of the head. In patients with intracranial hemorrhages, hematoma volumes were measured using the ABC/2 technique modified for ellipsoid chronic subdural hematoma (cSDH).\textsuperscript{14} The diagnosis was confirmed following adjudication by a cerebrovascular specialist and a neuroradiologist.

**RESULTS**

During the study period, of 13,500 patients with COVID-19 admitted to 6 different New York metropolitan tertiary care centers, 12 patients (8.8/10,000) had imaging-proved CVT. The demographic and clinical characteristics of our patients are summarized in the Online Supplemental Data.

The mean age in our cohort was 48 years (95% CI, 36–62 years) (interquartile range, 31–63 years) with 25% of patients younger than 25 years of age. Men accounted for 66% (8/12) of cases. 50% of the patients (6/12) were White. Prior prothrombotic risk was identified in only 17% (2/12) of patients (breast cancer and deep vein thrombosis). However, traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking) were identified in 58% (7/12) of patients.

Neurologic symptoms secondary to CVT occurred within 24 hours of the onset of the respiratory and constitutional symptoms (fever, cough, dyspnea, myalgia, and fatigue) in 58% (7/12) of patients. Of the remaining patients, 25% (3/12) developed CVT symptoms between 24 and 72 hours from symptom onset, and 16% (3/12) manifested CVT between 3 and 7 days from symptom onset.

Headache was the most common clinical neurologic symptom noted in 85% (10/12) of patients. Both seizures and hemiparesis occurred in 42% of patients. Cortical signs such as aphasia, neglect, or hemianopia were noted in only 25% of patients. Fever or cough was the most common symptom attributed to the COVID-19 infection and was noted in 75% (9/12) of patients.

Neuroimaging demonstrated focal brain injury in 75% of patients. Isolated hemorrhage (n = 4), venous infarction (n = 2), or venous infarction with hemorrhagic changes (n = 3) was about equally represented. Vessel imaging identified dural venous sinus thrombosis in 83% (10/12) of patients and isolated cortical vein thrombosis in 16% (2/12) of patients. Multiple dural sinuses were involved in 41% (5/12) of patients (Fig 1).

Anticoagulation was administered to 83% (10/12) of patients. Two patients were treated with endovascular thrombolysis (Fig 2). Hemicraniectomy was also performed in 2 patients. Of the 2 patients who did not receive treatment for their CVT, one patient died; and the second patient, who had a cortical vein as well as a nonocclusive superior sagittal sinus thrombosis, refused treatment.
Although all patients met the criteria for admission to the intensive care unit, mechanical ventilation was required in 41% of patients (5/12), and the median duration of ventilation was 15 days. One patient required a tracheostomy, while the remaining patients were successfully extubated. Acute renal failure was noted in 33% (4/12), acute liver failure occurred in 25% (3/12), and 8% (1/12) developed superimposed sepsis. One patient developed concomitant deep vein thrombosis. Hydroxychloroquine with or without azithromycin was administered to half (6/12) of the patients. No patients received steroids or remdesivir. Three patients (25%) were discharged home. Half (6/12) of patients were transferred to a rehabilitation facility (5 to acute rehabilitation and 1 patient to subacute rehabilitation). The mortality rate in our cohort was 25% (3/12).

**DISCUSSION**

Our findings on CVT in the setting of COVID-19, pooled from 6 tertiary care centers in the New York metropolitan area, demonstrate the predominance of individuals younger than 25 years of age in 25% of cases, with a male preponderance. Only 1 patient in our cohort was African American, despite the fact that Black individuals are more severely affected by severe COVID-19. In terms of risk factors, traditional thrombogenic risk factors were identified in only 1 of 12 patients, and 7 of 12 had traditional cardiovascular risk factors. Most patients (10 of 12) presented with headache, and half presented with seizures or unilateral weakness. This presentation is in addition to the fever and cough attributed to COVID-19 infection in 9 of 12 patients, with 5 of 12 requiring mechanical ventilation. Neuroimaging was significant for brain injury, including hemorrhage, venous infarction, venous infarction with hemorrhagic changes, dural venous sinus thrombosis, and isolated cortical vein thrombosis in most (9 of 12) patients. Ten of 12 patients were treated with anticoagulation, 2 with endovascular thrombolysis, 2 with hemicraniectomy, and 6 with hydroxychloroquine with or without azithromycin. Of the 2 patients who did not receive treatment for their CVT, one died; the other patient, who had a cortical vein as well as a nonocclusive superior sagittal sinus thrombosis, refused treatment.

We collected our cases during the height of the COVID-19 pandemic (March through May 2020). During this 3-month period, CVT was diagnosed in 12 of 13,500 hospitalized patients with COVID-19, for a frequency of 0.088 per million. By contrast, the reported incidence of CVT in the general population is 5 per million annually. The higher-than-expected rate of CVT among hospitalized patients with COVID-19, along with the well-established hypercoagulability that is known to occur with SARS-CoV-2 infection, supports a causal effect.

The literature demonstrates that 36%–59% of patients with COVID-19 have neurologic complications. Ischemic stroke incidence is estimated to be in the range of 5%, with a recent study demonstrating an unusual presentation of young patients with COVID-19 with arterial stroke. By contrast, cerebral venous sinus thrombosis (CVST) associated with COVID-19 is an exceedingly rare occurrence, with only 57 reports available at the time this writing (Online Supplemental Data). The average age of these previously reported patients is 53.5 years (range, 23–72 years), which is in agreement with our findings. Although we report a male preponderance, these 57 cases demonstrate an equal distribution of male and female patients. A direct comparison between our patients and those reported in the Online Supplemental Data is challenging in light of the substantial heterogeneity of demographic and clinical characteristics of patients with COVID-19 with CVST. Most previously reported patients had clinical CVST in a delayed fashion from initial symptoms attributable to COVID-19, whereas more than half of our patients presented with CVT concomitant with respiratory and constitutional symptoms. Because headache can be a common symptom of viral illnesses including COVID-19, diagnosis can often be elusive or delayed until symptoms worsen.

Patients with either no or minimal systemic and respiratory symptoms may first come to medical attention when they present with seizures or other symptoms attributed to the venous sinus thrombosis and are ultimately found to have COVID-19 infection.

While treatment guidelines for patients with COVID-19-related strokes are emerging, it is unclear whether any intervention can prevent these outcomes. Although anticoagulation is
being used prophylactically at many centers to prevent the thrombotic complications related to COVID-19, its benefit in stroke prevention remains to be seen. Two of our patients were on anticoagulation when their strokes were detected, and in one of those patients, the anticoagulation may have contributed to hemorrhagic conversion.

There have been several proposed mechanisms of neurologic manifestations following infection with coronaviruses. The virus may initially invade endothelial cells through angiotensin-converting enzyme receptors. The presence of viral elements within endothelial cells and an accumulation of inflammatory cells, with evidence of inflammatory cell death, have been demonstrated in patients with COVID-19. Inflammation of endothelial cells may cause cellular dysfunction, leading to either disruption of stable atherosclerotic plaque or circulatory changes in vascular beds, through a thrombogenic microvascular environment, manifesting as stroke, pulmonary embolism, or myocardial infarction. Critical SARS-CoV-2 infection is almost always accompanied by a significant proinflammatory response, which can activate the coagulation cascade through various pathways, leading to a profound prothrombotic state. This is consistent with 5 of 12 patients in our cohort having elevated D-dimer levels.

SARS-CoV-2 infection has also been linked to alternative and lectin complement cascade activation. These complement complexes can deposit on endothelial cells, leading to cellular damage, and can initiate a thrombotic microangiopathy. The presence of antiphospholipid antibodies and lupus antibodies has also been described in patients with COVID-19, though their clinical significance remains unknown.

Several caveats and weaknesses of this study deserve mention. Complete screening for pre-existing hypercoagulable states was not performed in all patients. However, the temporal association of CVT with respiratory and constitutional symptoms of COVID-19 in more than half of our patients suggests a causal effect. It is possible that some patients with CVT due to COVID-19 were not included in this series because their symptoms or signs were not properly diagnosed or charted. We were unable to compare baseline demographic and disease-related features between the CVT patient population and the main cohort of patients with COVID-19; this comparison might have allowed us to confirm male sex and identify other risk factors for CVT. Similarly, we also were unable to provide an estimate of the frequency of CVT among patients with COVID-19 who underwent brain imaging. Because all our patients were sick enough to be admitted to the hospital, multiple confounding factors could have contributed to our observed complications and outcomes. Additionally, because our sample of patients with confirmed CVT is limited to patients with COVID-19 who had neurologic issues, we are unable to assess the frequency of CVT in the overall COVID-19 cohort. It is also difficult to compare the incidence of CVT in the COVID-19 cohort with that of the general population due to differences in demographics between our cohort and the general population. Finally, the small number of included patients and restriction of our study population to the New York metropolitan area may limit the generalizability of our findings to other regions throughout the world. Larger analyses of this complication, such as a pooled meta-analysis, are warranted in the future, especially when more data become available.

CONCLUSIONS
SARS-CoV-2 has already infected millions of patients worldwide. Dreaded thrombotic complications, including CVST, have been reported in patients with SARS-CoV-2. As more reports of COVID-related CVST become available, it is hoped that our understanding of which patients are most at risk and the ideal treatment and prevention strategies can be elucidated.


REFERENCES